# LAI Weekly Intelligence – 2025-12-12

Newsletter generated in fallback mode (Bedrock error).

## LAI Technology & Innovation

**Nanexa and Moderna Announce PharmaShell Technology Partnership**  
Nanexa AB announces strategic partnership with Moderna to develop PharmaShell technology for extended-release injectable formulations.  
[Read more](https://nanexa.com/press-release-moderna-partnership)

**UZEDY (aripiprazole) Extended-Release Injectable Shows Positive Phase 3 Results**  
Teva Pharmaceutical announces positive Phase 3 clinical trial results for UZEDY, a novel extended-release injectable formulation.  
[Read more](https://tevapharm.com/uzedy-phase3-results)

---

## Funding & Business Development

**Nanexa and Moderna Announce PharmaShell Technology Partnership**  
Nanexa AB announces strategic partnership with Moderna to develop PharmaShell technology for extended-release injectable formulations.  
[Read more](https://nanexa.com/press-release-moderna-partnership)

**MedinCell Receives 2.5M Grant for Malaria Prevention LAI Development**  
MedinCell secures 2.5 million grant to advance development of long-acting injectable malaria prevention treatment using BEPO technology.  
[Read more](https://medincell.com/malaria-grant-announcement)

---

*Newsletter générée par Vectora Inbox – Powered by Amazon Bedrock*
